Use of an angiogenesis inhibitor as a lead compound in drug development
OwnerRoy E. Wuthier, Daotai Nieinventors
Life of this patent
Estimating the term…
Abstract
The present invention provides a treatment for angiogenic diseases, including solid tumors. The treatment consists of administering therapeutically active dosages of FC101, resulting in a reduction in endothelial cell proliferation and inhibition of new blood vessel formation. FC101 can also be used as a lead compound to develop other pharmacologically-active compounds, by adding or substituting different functional groups for those already present on the FC101 molecule.
Claims23
A method for inhibiting angiogenesis in human or animal patients, comprising administering to said patients a therapeutically active dosage of a water soluble fusarochromanone isolated from fungal cultures, wherein said water soluble fusarochromanone is administered via a pharmaceutically or veterinarily acceptable carrier, for a time effective to inhibit the formation of new blood vessels in said patient.
A method for treating angiogenic diseases in human or animal patients comprising administering to said patients a therapeutically active dosage of a water soluble fusarochromanone, wherein said water soluble fusarochromanone is administered via a pharmaceutically or veterinarily acceptable carrier for a time effective to treat the angiogenic disease.
A method for using FC101 as a lead compound to develop therapeutically active analogs, said method comprising the steps of:
- a) identifying a functional group member attached via a chemical bond to the structural backbone of the FC101 parent molecule, said members chosen from the group consisting of methyl, hydroxyl, amino, and acetyl functional groups.
- b) breaking the chemical bond joining said functional group member to said structural backbone of said FC101 parent molecule;
- c) removing said functional group member;
- and
- d) chemically joining a second member of said functional group to said structural backbone of said FC101 parent molecule.
A method for selectively inhibiting endothelial cell proliferation in human or animal patients, comprising treating said cells with a therapeutically active dosage of a water soluble fusarochromanone isolated from fungal cultures, wherein said fusarochromanone is administered in a pharmaceutically or veterinarily acceptable carrier for a time effective to inhibit endothelial cell proliferation in said patient.
Dependencies are inferred from the claim text.